Brachytherapy for prostate cancer

Atsunori Yorozu, Kazuhito Toya, Toshio Ohashi, Kae Ohsuga, Reiko Ito, Tomotaka Kasamatsu, Shiro Saito, Tetsuo Momma

研究成果: Review article

3 引用 (Scopus)


This review article aims to overview modern prostate brachytherapy in Japan. Permanent transperineal prostate brachytherapy with I-125 started in September, 2003 in Japan. Brachytherapy has several advantages: the dose is adapted precisely to the tumor shape and size, and the long-lived isotope gives a higher tumor dose with less damage to normal tissue; less-time consuming for patients and staff: long-term results comparable to surgery or external beam series in the USA; and quality of life after brachytherapy also appealing. These advantages have brought about increasing use in Japan as well. Patients with a high probability of organ-confined disease and a low-risk group are appropriately treated with brachytherapy. Brachytherapy candidates with a significant risk of extraprostatic extension should be treated with supplemental external beam radiation therapy. High-dose-rate (HDR) brachytherapy with Ir-192 has preceded seed implants in Japan. HDR has some theoretical advantages. Long-term results of brachytherapy in the USA are comparable with surgery or external beam irradiation so far. We should develop more sophisticated brachytherapy techniques in Japan.

ジャーナルGan to kagaku ryoho. Cancer & chemotherapy
出版物ステータスPublished - 2006 4


ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Yorozu, A., Toya, K., Ohashi, T., Ohsuga, K., Ito, R., Kasamatsu, T., Saito, S., & Momma, T. (2006). Brachytherapy for prostate cancer. Gan to kagaku ryoho. Cancer & chemotherapy, 33(4), 424-427.